At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Raltegravir and Maraviroc in Combination for the Treatment of Antiretroviral Naïve HIV-1 Infected Patients
In Brief
A clinical study evaluating Raltegravir and Maraviroc in combination for HIV Infections. Completed, enrolled 7 participants across 1 site.
Detailed Summary
This is a pilot, open-label study of raltegravir and maraviroc in combination for the treatment of antiretroviral naïve patients. The study will enroll 7 antiretroviral naïve patients with CD4 counts ≥ 350 and viral loads \> 5,000. The subjects will be followed for 48 weeks. The combination of these two agents has the potential to be a potent regimen with minimal metabolic complications. However, they have not been studied in combination previously. This pilot study proposes to evaluate this combination in antiretroviral naïve patients to document the safety and efficacy of this combination in order to provide clinicians with a treatment regimen that minimizes the risk of metabolic complications.
Study Details
Timeline
Interventions
Raltegravir 400 mg tablet twice a day, \~12 hours (10 to 14 hours) apart Maraviroc 300 mg tablet twice a day, \~12 hours (10 to 14 hours) apart